Business
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls
Seasoned regulatory and manufacturing executive with 20 approved market applications in the US and Europe and 50 regulatory submissions worldwide joins Citius
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Seasoned regulatory and manufacturing executive with 20 approved market applications in the US and Europe and 50 regulatory submissions worldwide joins Citius management team\n Strategic expertise in regulatory and chemistry, manufacturing and controls development spans multiple therapeutic areas including oncology, infectious diseases and cell therapy\n\n\nCRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs.\n\"With two late Phase 3 trials nearing completion, we continue to prepare the organization for commercial success. Kelly is a seasoned pharmaceutical veteran whose accomplishments include more than 50 investigational new drug (IND) submissions and 20 approved market applications spanning multiple therapeutic areas including oncology, infectious disease and cell therapy. Kelly has been a longstanding advisor to the Citius team on all aspects of the regulatory pathway for Mino-Lok® and we anticipate a seamless transition into this newly created in-house role. He brings an ideal blend of strategic thinking, leadership skills and deep global regulatory and product development expertise, which he will apply to our entire clinical program as we continue to develop the Citius pipeline,\" stated Myron Holubiak, Chief Executive Officer of Citius.\nKelly Creighton, PhD joins Citius from Clinipace Worldwide, a leading global contract research organization, where he served as Vice President of Regulatory and Strategic Development. As a senior-level regulatory affairs and quality assurance expert with nearly two decades of experience in biopharmaceuticals, pharmaceuticals, advanced therapies, including gene and cellular therapies, and combination products, he has provided comprehensive regulatory strategy assess...